S&P trims Arbor Pharmaceuticals

S&P said it downgraded its rating for Arbor Pharmaceuticals Inc. to B- from B.

“Our downgrade of Arbor reflects both our lowered sales expectations of the overall business and our expectation of weaker credit metrics. We are lowering our assessment of Arbor's overall business due to a pattern of underperformance from operational challenges, including manufacturing suspensions and stock-outs, canceled or delayed development projects and product underperformance,” S&P said in a press release.

The outlook is negative.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.